Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Spero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/04/2024 — Cantor Fitzgerald Reiterate
Buy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic Partnerships
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.2
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M
04:09 PM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M
Spero Therapeutics | 10-Q: Quarterly report
Express News | Spero Therapeutics Inc: Spr720 Top-Line Data From Phase 2a Proof-of-Concept Clinical Trial Are Expected in 2H 2024
Express News | Spero Therapeutics Inc: Received FDA Fast Track Designation for Spr206 for Treatment of Habp/Vabp Due to Crabc and Crpa
Express News | Spero Therapeutics Inc: Reiterate Expected Cash Runway Into Late 2025
Express News | Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Spero Therapeutics 1Q Rev $9.27M >SPRO
Spero Therapeutics 1Q Rev $9.27M >SPRO
Spero Therapeutics 1Q Loss/Shr 24c >SPRO
Spero Therapeutics 1Q Loss/Shr 24c >SPRO
Press Release: Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Notable Earnings After Wednesday's Close
Shareholders in Spero Therapeutics (NASDAQ:SPRO) Are in the Red If They Invested Three Years Ago
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm
Express News | Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
No Data